Table 2.

Detailed information of 28 flavonoids

No	Ingredients	Diseases	Use of cell lines	Mechanism of action	References
1	Fisetin	Non-small cell lung cancer	NCI-H460	↑p-ERK,↑p-JNK and ↑p–p38	Chen and Liu (2018)
2	Kaempferol	Oophoroma	OVCAR-3 and A2780/CP70	↓p-ERK	Chen and Liu (2018)
3	Quercetin	Liver cancer	HepG2	↑p-JNK, ↑p–p38,↓p-ERK1/2 and↓MEK1	Ding et al. (2018)
4	Chrysin	Oophoroma	ES2 and OV90	↑ERK1/2,↑JNK and↑p38	Lim et al. (2018a, b)
5	Luteolin	Cervical carcinoma	HeLa	↓p-ERK and ↓p–p38	Raina et al. (2021)
6	Baicalein	Colon cancer	HCT116,A549 and panc-1	↑p-ERK,↑p-JNK and↑p–p38	Su et al. (2018)
7	Apigenin	Bladder cancer	T24	↓p-ERK1/2 and ↓p-JNK	Xia et al. (2018)
8	7,8-dihydroxyflavone	Osteosarcoma	U2OS and 143B	↓p–p38,↑p-JNK,↑p-ERK1/2	Zhao et al. (2021a, b)
9	Myricetin	Osteosarcoma	D-17 and DSN	↑p-JNK and↑p-ERK1/2	Park et al. (2018b, a)
10	Quercetin-3-methyl ether	Esophageal squamous cell carcinoma	KYSE450 and KYSE510	↓p-ERKs	Zhao et al. (2018)
11	3,4',7-O-trimethylquercetin	Ovarian cancer	CRL-1978	↓p38	Ashraf et al. (2018)
12	Eupatilin	Esophageal cancer	TE1	↓p-ERK1/2	Wang et al. (2018a, b, c, d)
13	Jaceosidin	Breast cancer	MCF-7	↑p-ERK and↑p–p38	Ojulari et al. (2021)
14	Chrysosplenol D	Oral squamous cell carcinoma	SCC-9 and HSC-3	↓p-ERK1/2,↓p-JNK1/2 and ↓p–p38	Hsieh et al. (2021)
15	Sideroxylin	Oophoroma	ES2 and OV90	↑p-ERK1/2,↑p-JNK and↑p–p38	Park et al. (2018b, a)
16	Genistein	Non-small cell lung cancer	NCI-H460	↑p-ERK,↑p-JNK and↑p–p38	Chen and Liu (2018)
17	Tectorigenin	Breast cancer	MDA-MB-231 and MCF-7	↓p-ERK, ↓p-JNK and ↓p–p38	Yang et al. (2021)
18	3-deoxysappanchalcone	Esophageal squamous cell carcinoma	KYSE 30/70/410/450/510	↑p-JNK and↑p–p38	Kwak et al. (2021)
19	Cardamonin	Osteosarcoma	OS	↑p-JNK and↑p–p38	Zhang et al. (2021a, b, c)
20	Eriodictyol	Glioblastoma	A172 and U87 MG	↓p–p38	Lv et al. (2021)
21	Slaidroside	Colorectal cancer	HT29	↑JNK and↑p38	El-Kott et al. (2021)
22	Sophoraflavanone G	Triple negative breast cancer	MDA-MB-231	↓p-ERK1/2,↓p-JNK and ↓p–p38	Yang et al. (2021)
23	Puerarin	Non-small cell lung cancer	NSCLC	↓p-ERK	Hu et al. (2018)
24	(-)-epigallocatechin gallate	Triple negative breast cancer	MDA-MB-231	↓p-ERK	Huang et al. (2021a, b)
25	Delphinidin	Melanoma	HOS and MG-63	↓p-ERK and ↓p–p38	Kang et al. (2018)
26	Calycosin	Gastric cancer	AGS	↑p-JNK, ↑p–p38 and ↓p-ERK	Zhang et al. (2021a, b, c)
27	Gambogic Acid	Prostatic cancer	PTEN-//p53-/PC and LAPC-4	↓ERK1/2 and↓p-MEK1/2	Pan et al. (2018)
28	Luteoloside	Cervical carcinoma	Hela	↑p-JNK and↑p–p38	Shao et al. (2018)